Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/9039
Title: | COVID-19 Infection in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor in Makassar, Indonesia: A Six-Case Report and Literature Review |
Authors: | Harjianti, Tutik Benyamin, Fachrudin Minhajat, Rahmawati Saleh, Sahyuddin Bayu, Dimas Pababbari, Wahyudi |
Keywords: | Chronic Myeloid Leukemia, Tyrosine Kinase Inhibitor, COVID-19, Case Report |
Issue Date: | 1-Jul-2023 |
Publisher: | Perhimpunan Dokter Spesialis Penyakit dalam Indonesia |
Abstract: | ABSTRACT Management of chronic myeloid leukemia (CML) in patients who are infected with COVID-19 is a challenging task due to disease-related or treatment-related factors that place such patients at a higher risk of complications. However, a low-infectivity-rate mechanism has been proposed by some researchers. In CML patients with COVID-19 infection, the most important treatment-related factor involves tyrosine kinase inhibitors (TKIs). In this case report, six patients with chronic-phase CML who experienced COVID-19 of mild–moderate severity all continued to receive TKI treatment for CML concurrently with COVID-19 treatment. All patients fully recovered. In the present study, we also review four other cases of COVID-19 infection in CML patients. Outcomes for TKI-treated CML patients who contract COVID-19 are influenced by many factors. Tyrosine kinase inhibitor therapy may benefit CML patients due to its antiviral effect, but the interaction between TKIs and drugs used for COVID-19 treatment requires careful monitoring. An individual approach is needed in every case. Keywords : Chronic Myeloid Leukemia, Tyrosine Kinase Inhibitor, COVID-19, Case Report |
URI: | http://localhost:8080/xmlui/handle/123456789/9039 |
ISSN: | 2338-2732 |
Appears in Collections: | VOL 55 NO 3 2023 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
332-338.pdf | 366.28 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.